您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > BI6727(Volasertib)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
BI6727(Volasertib)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
BI6727(Volasertib)图片
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
5mg电议
10mg电议
50mg电议
100mg电议

产品介绍
BI6727(Volasertib) (BI 6727) 是一种具有口服活性、高效和 ATP 竞争性的 Polo 样激酶 1 (PLK1) 抑制剂,IC50 为 0.87 nM。 BI6727(Volasertib) 抑制 PLK2 和 PLK3,IC50 分别为 5 和 56 nM。 BI6727(Volasertib) 诱导有丝分裂停滞和细胞凋亡。 BI6727(Volasertib) 是一种二氢蝶啶酮衍生物,在多种癌症模型中显示出显着的抗肿瘤活性。

Cell lines

Human melanoma A375 and Hs 294T cells

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

24 h, 10-100 nM

Applications

BI6727 (Volasertib) is a second generation small molecule Plk1 inhibitor and has been reported to be a promising agent for treatment of several cancers. BI6727 (Volasertib) inhibits growth, viability and induces apoptosis of melanoma cells.

Animal models

Patients aged ≥ 18 years with locally advanced or metastatic urothelial cancer

Dosage form

BI6727 (Volasertib) was administered by 2-hour intravenous infusion at a dose of 300 mg once daily on day 1 of 3-week treatment cycles.

Application

BI6727 (Volasertib) has an acceptable safety profile as a second-line treatment for advanced or metastatic urothelial cancer, but only modest antitumor activity for further evaluation as a monotherapy.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

产品描述

BI6727 (Volasertib) is a selective inhibitor of Plk1, Plk2, and Plk3 with IC50 value of 0.87, 5 and 56 nM/L, respectively [1].

Polo-like kinase 1 (Plk1) is an early trigger for G2/M phase transition and is over-expressed in a variety of cancers for that being regarded as a promising target for cancer treatment [1].

BI6727 (Volasertib) is a potent Plk1 inhibitor and is regarded as a promising drug for multiple cancers in clinic. When tested with NB TICs and normal human pediatric SKPs (neural crest-like stem cells), BI6727 (Volasertib) treatment inhibits NB TICs with EC50 value of 21 nM/L and 2.8 μM/L on SKPs and decresed TIC survival [2]. It has been reported that BI6727 (Volasertib) inhibited proliferation of multiple cell lines, including HCT 116(caicinomas of the colon), NCI-H460 (lung cancer), BRO (melanoma), GRANTA (hematopoitic cancers) with EC50 value of 23 nmol/l, 21 nmol/l, 11 nmol/l, 15 nmol/l, respectively [1] [3].

In nude mice model with HCT 16 cells (colon carcinoma) subcutaneous xenograft, oral administration of BI6727 (Volasertib) delays tumor growth, decreased tumor size and induced tumor regression by increasing the mitotic index and apoptosis. And the same results were achieved when tested with NCI-H4660 (non-small cell lung carcinoma), xenograft model [1].

References:
[1].  Rudolph, D., et al., BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res, 2009. 15(9): p. 3094-102.
[2].  Grinshtein, N., et al., Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Cancer Res, 2011. 71(4): p. 1385-95.
[3].   Munch, C., et al., Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines. Leuk Res, 2015. 39(4): p. 462-70.